Nuvation Bio posts corporate deck highlighting IBTROZI ROS1+ NSCLC launch, safusidenib IDH1 glioma program

Reuters2026/07/20 12:18

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Nuvation Bio highlighted IBTROZI (taletrectinib) as a commercial driver, with U.S. net product revenue of USD 43 million as of March 31, 2026.
IBTROZI is marketed for advanced ROS1+ NSCLC in the U.S., Japan, China; EMA validated its marketing authorisation application.
Pro forma cash balance pegged at about USD 736 million, positioned as sufficient to reach profitability without additional funding.
Safusidenib positioned as a brain-penetrant IDH1 inhibitor, with a pivotal SIGMA study enrolling in IDH1-mutant glioma.
Drug-Drug Conjugate platform remains preclinical, with candidates designed to bind two targets simultaneously.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief on July 20, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Nuvation Bio posts corporate deck highlighting IBTROZI ROS1+ NSCLC launch, safusidenib IDH1 glioma program

You may also like

Crypto prices